Beigene on SPi NewsFollow our SPi News RSS Feed for beigene

Featured beigene News

[08 Aug 2019] BeiGene Reports Second Quarter 2019 Financial Results

[09 May 2019] BeiGene Reports First Quarter 2019 Financial Results

[04 Mar 2019] BeiGene to Present at Upcoming Investor Conferences

[22 Feb 2019] BeiGene to Present at the 8th SVB Leerink Global Healthcare Conference

[07 Feb 2019] BeiGene to Present at the Guggenheim Healthcare Talks Idea Forum – Oncology Day

[03 Jan 2019] BeiGene Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

[05 Dec 2018] BeiGene Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

[20 Nov 2018] BeiGene to Present at the 30th Annual Piper Jaffray Healthcare Conference

[13 Nov 2018] BeiGene Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

[07 Nov 2018] BeiGene Reports Third Quarter 2018 Financial Results

[01 Oct 2018] BeiGene Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

[25 Sep 2018] BeiGene to Present at Upcoming Investor Conferences

[04 Sep 2018] BeiGene Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

[09 Aug 2018] BeiGene Reports Second Quarter 2018 Financial Results

[03 Jul 2018] BeiGene Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

[05 Jun 2018] BeiGene to Present at the William Blair 2018 Growth Stock Conference

[09 May 2018] BeiGene Reports First Quarter 2018 Financial Results

[02 May 2018] BeiGene Appoints Senior Pharmaceutical Executive Dr. Xiaobin Wu as General Manager of China and President of BeiGene, Ltd.

[03 Apr 2018] BeiGene Appoints J. Samuel Su to its Board of Directors

[05 Mar 2018] BeiGene to Present at Upcoming Investor Conferences

[07 Feb 2018] BeiGene to Present at the LEERINK Partners 7th Annual Global Healthcare Conference

[05 Feb 2018] BeiGene Announces Commercial Availability of VIDAZA® (Azacitidine for Injection) in China

[22 Jan 2018] BeiGene Announces Closing of $800 Million Public Offering

[18 Jan 2018] BeiGene Announces Pricing of $750 Million Public Offering

[16 Jan 2018] BeiGene Announces Proposed Public Offering

[17 May 2017] BeiGene to Present at the 2017 UBS Global Healthcare Conference

[10 May 2017] BeiGene Reports First Quarter 2017 Financial Results

[06 Apr 2017] Myriad Genetics and BeiGene Sign Agreement to Develop Companion Diagnostics for Use with BeiGene’s Novel PARP Inhibitor, BGB-290

[02 Mar 2017] BeiGene Announces Initiation of First Pivotal Study in China with BTK Inhibitor BGB-3111

[08 Feb 2017] BeiGene to Participate in the LEERINK Partners 6th Annual Global Healthcare Conference

[21 Dec 2016] BeiGene Announces First Patient Dosing in China with Investigational PARP Inhibitor BGB-290

[23 Nov 2016] BeiGene Announces Closing of $200 Million Public Offering

[18 Nov 2016] BeiGene Announces Pricing of $200 Million Public Offering

[16 Nov 2016] BeiGene Announces Proposed Public Offering

[10 Nov 2016] BeiGene Reports Third Quarter 2016 Financial Results

[01 Nov 2016] BeiGene to Participate in 25th Annual Credit Suisse Healthcare Conference

[04 Oct 2016] BeiGene to Host Conference Call on BGB-3111 Data Presentation at IWWM-9

[06 Sep 2016] BeiGene Appoints Jane Huang, M.D. as Chief Medical Officer, Hematology

[31 Aug 2016] BeiGene to Participate in Baird and Morgan Stanley Global Healthcare Conferences

[24 Aug 2016] BeiGene Appoints Amy Peterson, M.D. as Chief Medical Officer, Immuno-oncology

[10 Aug 2016] BeiGene Reports Second Quarter 2016 Financial Results

[05 Jul 2016] BeiGene Announces First Patient Dosing for Investigational BTK Inhibitor BGB-3111 in China

[11 May 2016] BeiGene Reports First Quarter 2016 Financial Results

[11 Apr 2016] BeiGene Appoints Eric Hedrick, M.D. as Interim Chief Medical Officer

[07 Mar 2016] BeiGene Receives Approval to Initiate Clinical Trials in China With BGB-3111

[08 Feb 2016] Citi Appointed Depositary Bank for BeiGene, Ltd.’s Sponsored ADR Program

[08 Feb 2016] BeiGene Announces Closing of Its Initial Public Offering

[03 Feb 2016] BeiGene Announces Pricing of Its Initial Public Offering

[11 Sep 2015] BeiGene Announces the Addition of Dr. Jedd D. Wolchok to Scientific Advisory Board

[14 Jul 2015] BeiGene Doses First Patient in Phase Ib Study of BGB-283, a Novel Second Generation B-RAF Inhibitor


Still looking?

Type in your search term below and click Enter

World News from SPi

Sector Publishing Intelligence [SPi'] publishes financial news from around the world FAST. For breaking news announcements from companies, blogs and commentators, SPi provides up to the minute, integrated news on all aspects of financial markets and financial services.

SPi's extensive database of corporate information shows company details alongside breaking corporate news from the world’s largest news providers.

Publish Your Stories with SPI

Please click here to find out how to submit press releases and articles for publication.

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
 
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 07519380.
 
Privacy Policy | Terms and Conditions | Contact Us